RxDoctor Payments DataLook up a doctor →

John Harness

Podiatrist · Overland, MONPI 1649272493

Payments from drug & device makers

$13,629in general payments, 2019–2025

Across 349 payments — averaging $39.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$6K
  • Integra Lifesciences Corporation$4K
  • Koya Medical, Inc.$736
  • Tactile Systems Technology Inc$662
  • Smith+Nephew$654
  • Organogenesis Inc.$450
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$3,00322%
  • Food & beverage$10,39476%
  • Other$2322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,629 in reported general payments places this provider in the 95th percentile of 105 podiatrist providers in Missouri.

See all podiatrist providers in Missouri

Medicare billing

Part B allowed, 2024
$1,194,496
Medicare patients
353
Services billed
4,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.33$33,320
Betamethasone Dipropionate121$6,114
Clotrimazole340$4,925
Celecoxib138$2,201
Ciclopirox43$1,239
Pregabalin49$896
Doxycycline Hyclate111$850
Ammonium Lactate55$819
Diclofenac Sodium11$619
Terbinafine Hcl47$488
Gabapentin79$479
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$220
Metronidazole25$151
Levofloxacin41$149
Ciprofloxacin Hcl11$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$654$33,32033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 podiatrist providers in Missouri.

Other podiatrist in Overland

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →